Dihydroergocriptine in Management of Microprolactinomas*
Authors:
- Antonio ContiACAntonio Conti
- Milena MuratoriMMMilena Muratori
- Emma TogniETEmma Togni
- Pietro TravagliniPTPietro Travaglini
- Annalisa ZanottiAZAnnalisa Zanotti
- Federico MaillandFMFederico Mailland
- 1 October 1987
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 65 (4) , 779-784
Abstract
The effects of dihydroergocriptine (DHECP), a dihydrogenated ergot alkaloid with dopaminergic agonistic and .alpha.-adrenergic antagonistic properties, were studied in 22 women with PRL-secreting microprolactinomas and compared with those recorded in 36 previously studied patients treated with bromocriptine (BRC). After acute administration of 5 mg DHECP, orally, serum PRL decreased by 61 .+-. 18% (.+-.SD); only 1 patient was unresponsive. The nadir was reached at 300 min. Long term treatment with increasing DHECP doses caused a progressive PRL fall from 125 .+-. 142 (.+-.SD) to 81 .+-. 159 .mu.g/L after 1 week of a 3 mg twice daily regimen, to 64 .+-. 88 .mu.g/L after 1 week of 5mg twice daily, 46 .+-. 57 .mu.g/L after 1 week of 10 mg twice daily, and 28 .+-. 34 to 33 .+-. 45 .mu.g/L throughout 9 months of treatment with 10 mg DHECP 3 times daily. Seventy-seven percent of patients had normal serum PRL levels during chronic treatment. All women, including those with supranormal serum PRL levels, resumed regular menses, and 16 had ovulatory cycles: 1 woman became pregnant. Galactorrhea disappeared in all. During treatment the PRL response to TRH, initially absent in all patients, became positive in 10. In 7 patients, after DHECP treatment for 9 months, high definition computed tomographic scan no longer showed the focal lesions initially seen. After drug withdrawlal, serum PRL increased again in all except 1 patient. Two patients had regular menses for 6 months, and 3 still had no adenoma imaged by high definition computed tomography. In BRC-treated patients the serum PRL changes and clinical results were very similar to those in the DHECP-treated patients, except for the persistence of normal serum PRL levels in 4 patients after drug withdrawal. On the other hand, side-effects were negligible during DHECP treatment, but remarkable during BRC. Systolic and diastolic blood pressures decreased by only 5.4 and 3.0 mm Hg, respectively, after acute 5 mg DHECP administration, but decreased by 12.8 and 14 mm Hg after acute 2.5 mg BRC administration. Orthostatic hypotension and peripheral vasomotor phenomena occurred in the long term DHECP treated patients except one, but they occurred in 9 and 3 of those treated with BRC, respectively. Gastric discomfort or mild nausea occurred in 12 DHECP-treated patients, while mild or severe nausea or vomoting were observed in 18, 11, and 2 of those taking BRC, respectively. All patients tolerated 30 mg DHECP very well, while 2, 7, and 7 patients did not tolerate more than 2.5, 5.0, or 7.5 mg BRC, respectively. Six patients who did not tolerate BRC were treated with DHECP, and they had no significant side-effects. We conclude that DHECP is an effective and well tolerated PRL-lowering drug that may be useful for medical therapy of pathological hyperprolactinemia.Keywords
This publication has 15 references indexed in Scilit:
- Bromocriptine Treatment of Microprolactinomas: Evidence of Stable Prolactin Decrease after Drug Withdrawal*The Journal of Clinical Endocrinology & Metabolism, 1985
- Mesulergine, a new dopamine agonist: Effects on anterior pituitary function and kineticsClinical Pharmacology & Therapeutics, 1984
- HyperprolactinemiaThe American Journal of Medicine, 1983
- Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.Molecular Pharmacology, 1983
- Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditionsEuropean Journal of Endocrinology, 1983
- [3H]Dihydroergocryptine Binding in Anterior Pituitary and Prolactin Secretion: Further Evidence of Brain Regulation of Adenohypophyseal Receptors*Endocrinology, 1980
- Metergoline Treatment of Hyperprolactinemic StatesFertility and Sterility, 1979
- Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release.Journal of Biological Chemistry, 1978
- [3H]Dihydroergocryptine binding in rat brainBrain Research, 1977
- Alpha-Adrenergic Receptor Identification by [ 3 H]Dihydroergocryptine BindingScience, 1976